S
Shark Tooth Biotech focuses on developing therapeutic treatments for Charcot-Marie-Tooth Disease Type 1A (CMT1A) by leveraging existing, proven RNA science and delivery technologies. The company employs a "Drug Assembly" approach, partnering with leading labs to test proprietary technologies for application to CMT1A. This strategy aims to accelerate the path to an effective treatment for this peripheral neuropathy and potentially unlock solutions for other related nerve diseases.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Shark Tooth Biotech focuses on developing therapeutic treatments for Charcot-Marie-Tooth Disease Type 1A (CMT1A) by leveraging existing, proven RNA science and delivery technologies. The company employs a "Drug Assembly" approach, partnering with leading labs to test proprietary technologies for application to CMT1A. This strategy aims to accelerate the path to an effective treatment for this peripheral neuropathy and potentially unlock solutions for other related nerve diseases.